Key points:
- The article talks about four stocks that are under $2 and insiders are buying them.
- Airship AI Holdings is a company that uses AI to help with safety and efficiency in different areas, and it has a big contract with the government.
- Lineage Cell Therapeutics is a company that works on a treatment for spinal cord injuries and has submitted its product to the FDA for approval. Read from source...

1. The title of the article is misleading and clickbaity. It does not clearly state what the insiders are buying or why it matters to the average investor. A better title would be something like "Insider Trades: Four Stocks Under $2 That May Interest Investors".

Positive
Analysis: The article highlights insider buying of stocks under $2, which indicates confidence in the companies and their future prospects. It also mentions Airship AI Holdings winning a government contract worth $10.9 million, which is a positive development for the company. Additionally, Lineage Cell Therapeutics submitted an investigational new drug amendment to the FDA for OPC1, which could potentially treat spinal cord injuries and bring more value to the stock. These factors contribute to a positive sentiment around these stocks.

- Airship AI Holdings (AISP) has strong growth potential as it recently started delivery of $10.9 million U.S. government contracts for advanced video and sensor management, which could boost its revenues and market share in the surveillance industry. However, there are also risks involved such as competition from other AI-driven platforms, regulatory changes, and potential cybersecurity threats that could affect its performance and stock price.
- Lineage Cell Therapeutics (LCTX) has a promising pipeline of regenerative medicine products, including OPC1 for spinal cord injury, which could provide significant clinical benefits and commercial opportunities if approved by the FDA. However, there are also risks involved such as regulatory uncertainty, clinical trial setbacks, and competition from other players in the field that could affect its development timeline and stock price.
- Longeveron (LGVN) is a biotech company focused on developing allogeneic cell therapy products for various diseases and conditions, such as ALS, heart failure, and diabetes. It has partnered with the University of Miami and the NIH to advance its research and clinical trials. However, there are also risks involved such as limited clinical data, lack of marketing approval, and competition from other cell therapy companies that could affect its growth prospects and stock price.
- Globalstar (GSAT) is a satellite communications company that provides mobile voice and data services to customers in remote and rural areas. It has recently launched new satellite constellations and upgraded its network infrastructure to improve its service quality and coverage. However, there are also risks involved such as intense competition from other satellite and wireless providers, regulatory changes, and technological obsolescence that could affect its revenues and stock price.